Syed Ehsan Shah on Advantages of Werfen HemoCell Automation
Syed Ehsan Shah, Hemostasis Key Account Manager at Werfen, shared on LinkedIn:
”This week in Basel, Switzerland Werfen EEMEA together with AFMS team hosted a one-day session on automation in Hemostasis laboratories for our customers from Saudi Arabia.
It was a great opportunity to share knowledge about Werfen Hemostasis Solutions for big specialized hemostasis centers and explore how Werfen automation-HemoCell can truly transform daily hemostasis lab operations.
In the afternoon, participants had the chance to see the HemoCell automation in action in Basel University.
The laboratory supervisor shared valuable insights, highlighting key advantages such as:
- Less than 30 minutes turnaround time
- Full sample traceability
- Complex reflex rules for factor assays
- Reduced staff workload
A big thanks to all the participants and our team members who joined and contributed to the discussions — it’s always inspiring to see how Werfen innovation in Hemostasis continues to enhance lab efficiency and patient care.
Special thanks to Elias Bouchi, Gianpaolo Pozzato and Ahmed Abbas for your support and dedication.”

Stay updated with Hemostasis Today.
-
Dec 18, 2025, 17:13Daria Camilli on EuroBloodNet and EHC Collaboration for Bleeding Disorders
-
Dec 18, 2025, 16:50Marie Cambot on Innovhem’s Quantification of The HbF/HbS Ratio for SCD
-
Dec 18, 2025, 16:26Yogesh Rathod on Hematological Issues and ICU
-
Dec 18, 2025, 16:09Carlos Doti: I’m Reminded Why ASH is Such a Powerful Close to The Year
-
Dec 18, 2025, 15:23Michael Hadley: Well-Timed ACC Statement Just Out in JACC Journals
-
Dec 18, 2025, 15:12Wolfgang Miesbach on Insights from Guy Young’s ASH2025 Session on Next-Generation Gene Therapy
-
Dec 18, 2025, 14:15Plasma-Derived Therapy for Hemophilia in The Updated European Medicines Agency’s Union List
-
Dec 18, 2025, 13:55Laurent Bertoletti: BAT-VTE is One of 7 Projects Funded Under the EFFECT Trial Call!
-
Dec 18, 2025, 13:34Alexandru Stieber Explores VEXAS Syndrome
